measurement of enzyme activity showed a high correlation to the enzyme protein measurement method, the numerical values for the two methods differed. This is probably explained by a difference in standard and sample (12; and Isaksson and Hultberg, manuscript in preparation): the standard contained placental Hex A or Hex B.
Materials and Methods

Clinical Specimens
Blood samples were collected into tubes containing EDTA as anticoagulant.
In the clinical trial, six patients received a low oral doseof CsG (5 mg/kg per day), which was tapered to 4 mg/kg per day beginning at week 4 after transplantation and further reduced to 2. and at weeks 4 to 8 and 8 to 16, respectively. These target values for low-and high-dose regimens of CsG measured by RIA were recommended by Sandoz Pharmaceuticals (East Hanover, NJ) to be used in a 4-month, multicenter, randomized dose-ranging study in patients receiving a renal transplant.
A group of six patients also received CsA (10 mg/kg per day), which was tapered to 8 mg/kg per day at the beginning of week 4 after transplantation and then to 5 mg/kg per day starting at week 8. CsA was measured in these patients' samples by HPLC.
All transplant patients were also receiving azathioprine and prednisone, and any patients receiving drugs thought to interfere with measurements of CsG blood concentrations were excluded from the study. These drugs included nephrotoxic drugs such as ketoconazole, 
Assays
CsG by HPLC. The HPLC procedure was a modification of a method previously described (8). The modified procedure was as follows: we vortex-mixed for 30s1 mL of patient's sample or control with 3 mL of an internal standard reagent containing CaC (100 ,ug'L) in methanol, acetonitrile, and water (50/30/20, by vol) and zinc sulfate (50 g/L). The samples were then centrifuged at 4000 x g for 5 mm and the supernates were transferred to Bond Elut C18 bonded-phase extraction columns (Analytichem International, Harbor City, CA 
Whole-blood
CsG calibrators ranging from 0 to 1500 gfL, prepared as for the RIA, were substituted for CsA calibrators. As with the RIA, in-house studies showed that the antibody cross-reacted 100% with CsG over the range 0-1500 pg/b. The assay was carried out by using the Abbott TDx analyzer similarly to the whole-blood CsA polyclonal assay previously described (9).
Assay Evaluation
Detection limit and linearity.
For HPLC, RIA, and FPIA, assay sensitivity (detection limit) was assessedby assaying 20 blood-donor whole-blood samples with zero concentrations of CsG and calculating the mean ±2 SD for the samples. We also subdivided the data in accordance with low-and high-dose CsG, considering 47 and 60 samples for each dose,respectively. 
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DIscussIon
CsG is a member of a class of compounds produced by the fungus Tolypocladium inflatum GAMS that have marked immunologic activity.
CsA, the most extensively studied compound of the group, has been very successfully applied in clinical use as an immunosuppressant in organ transplantation.
The major problem with the clinical use of CsA is its propensity to produce nephrotoxicity in patients at a wide range of doses.CsG is very similar in structure to CsA and has been reported to lack nephrotoxicity in a rat model (3) . Further, CsG has been shown to be as potent as CsA in preventing rejection of transplanted livers in a canine model
(5).
In this study, CsG was administered at two oral doses and HPLC, RIA, and FPIA were assessed for their capability to provide accurate and precise determinations of CsG after surgery. We also wanted to know whether any of the methods would be useful for rapid pharmacokinetic studies in patients receiving a bolus of CsG after renal transplantation.
The methods considered were analytically acceptable for the measurement of CsG in whole blood. The HPLC assay was suitably sensitive, accurate, and precise. CsG may also be measured by RIA and FPIA with the use of available reagents for assay of CsA, due to the cross-reactivity of the monoclonal antibodies with CsG. In this report both CsA and CsG gave concentrationresponse curves that were superimposable. However, in these immunoassays, we prepared CsG calibrators inhouse for routine use, using donor whole blood. Considering that standardization problems with CsA determinations have arisen in the past, we recommend that laboratories undertaking such CsG studies prepare in. house calibrators (10, 11) .
In this study, reasonable correlation was obtained when comparing RIA and FPIA with HPLC for 107 patients' samples. FPIA and RIA both gave superior correlation data in terms of regression-line slope, intercept, and standard error of the estimate, possibly because both techniques incorporate the same monoclonal antibody developed against CsA. When both low-and high-dose CsG groups were compared, findings were not significantly different from when combined data from the two groups were analyzed.
These results are interesting, given our recent studies comparing HPbC, RIA, and FPIA for the measurement of CsA in whole blood (11). In that report we obtained the following data for adult renal transplant recipients (n = 50) receiving CsA RIA = 1. Table 2 ) and indicated that interference from CsG metabolites may be less of a problem in the immunoassays consid 
